By converting TGF-β from an immunosuppressant to an immunostimulant, these engineered CAR-T cells enhanced T-cell infiltration and reduced suppressive myeloid cells, improving survival in preclinical GBM models (Hou et al., 2024). This evidence concerns the gene TGFB1 and glioblastoma.